Literature DB >> 1895978

Failure to demonstrate contrast nephrotoxicity.

C A Heller1, J Knapp, J Halliday, D O'Connell, R F Heller.   

Abstract

OBJECTIVE: We tested the hypothesis that there is no difference in the change in serum creatinine level following computed tomography (CT) between those given high osmolality contrast, low osmolality contrast and those not receiving contrast material.
DESIGN: Patients were assigned according to current radiological practice to receive one or other type of radiocontrast material or to have a scan without intravenous contrast (plain scan).
SETTING: The CT unit of Royal Newcastle Hospital, a tertiary referral institution. PATIENTS: Of 3188 inpatients having a CT scan between June 1988 and December 1989, 1041 patients were eligible (having a first scan in "office hours" outside holiday periods, not due for imminent discharge, aged 18 years or more and not presenting to the Intensive Care Unit or with acute trauma). Twenty-five patients were excluded as baseline measures of renal function were missing and 132 subjects were lost to follow-up, leaving 884 study subjects.
INTERVENTIONS: CT scans using high osmolality, low osmolality or no contrast (plain scan). MAIN OUTCOME MEASURE: Renal impairment as defined by a maximal increase in the serum creatinine level of greater than or equal to 50% or greater than 0.04 mmol/L from the baseline level on at least one of the subsequent four days.
RESULTS: Renal impairment was seen in 4% (12 of 292), 12% (23 of 187) and 4% (16 of 405) of patients given high osmolality, low osmolality or no contrast respectively. Age and the baseline level of serum creatinine were independent predictors of the development of renal impairment (P = 0.04 and 0.02 respectively) and those given low osmolality contrast were 3.2 times (95% confidence interval, 1.6-6.3) more likely to develop renal impairment than those given no contrast. There was no excess risk with the use of high osmolality contrast compared to no contrast (odds ratio, 1.06; 95% confidence interval, 0.5-2.3). Selection factors (sicker patients being given low osmolality contrast) are likely to have accounted for the excess risk in the low osmolality group as mortality in hospital was higher in this group than in the others. The 51 patients who developed renal impairment (cases) were matched for age, sex, type of contrast and pre-existing renal impairment with up to three controls (150 patients in total). Cases were more likely to have had a blood transfusion (odds ratio, 6.40; 95% confidence interval, 2.18-22.63) or surgery (odds ratio, 3.22; 95% confidence interval, 1.19-7.65) than controls.
CONCLUSIONS: Confounding by other factors which impair renal function is likely to explain previous suggestions of an effect of radio-contrast material on renal function. There does not appear to be a risk of renal impairment from the use of high osmolality radiocontrast material (although a small effect or an effect in particular subgroups cannot be excluded by our study). Fear of causing or exacerbating renal damage should not be a reason to use low osmolality contrast material, nor should it be a reason for with-holding contrast studies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1895978     DOI: 10.5694/j.1326-5377.1991.tb142293.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  18 in total

1.  Changing Paradigms in Contrast Nephropathy.

Authors:  Arnaldo Lopez-Ruiz; Kiran Chandrashekar; Luis A Juncos
Journal:  J Am Soc Nephrol       Date:  2017-01-19       Impact factor: 10.121

Review 2.  Updated guidelines for intravenous contrast use for CT and MRI.

Authors:  Kevin Huynh; Arthur H Baghdanian; Armonde A Baghdanian; Derek S Sun; K Pallav Kolli; Ronald J Zagoria
Journal:  Emerg Radiol       Date:  2020-01-10

3.  Coadministration of Liposomal Amphotericin B and Contrast Medium Does Not Increase Risk of Kidney Injury.

Authors:  John C O'Horo; Douglas R Osmon; Omar M Abu Saleh; Jasmine R Marcelin; Kamel A Gharaibeh; Abdurrahman M Hamadah; Amelia K Barwise; Bryce M Kayhart; Jennifer S McDonald; Robert J McDonald; Nelson Leung
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

4.  Prevention of Contrast-Induced Nephropathy (CIN) in Interventional Radiology Practice.

Authors:  Rajan K Gupta; Tami J Bang
Journal:  Semin Intervent Radiol       Date:  2010-12       Impact factor: 1.513

5.  Contrast-induced nephropathy in patients with renal insufficiency undergoing contrast-enhanced MDCT.

Authors:  Ryusuke Murakami; Hiromitsu Hayashi; Ken-Ichi Sugizaki; Tamiko Yoshida; Emi Okazaki; Shin-Ichiro Kumita; Chojin Owan
Journal:  Eur Radiol       Date:  2012-05-02       Impact factor: 5.315

6.  No increased risk for contrast-induced nephropathy after multiple CT perfusion studies of the brain with a nonionic, dimeric, iso-osmolal contrast medium.

Authors:  S Langner; S Stumpe; M Kirsch; M Petrik; N Hosten
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-04       Impact factor: 3.825

7.  Risk of contrast-induced nephropathy in hospitalized patients with cirrhosis.

Authors:  Nilesh Lodhia; Michael Kader; Thalia Mayes; Parvez Mantry; Benedict Maliakkal
Journal:  World J Gastroenterol       Date:  2009-03-28       Impact factor: 5.742

8.  Estimating the Risk of Radiocontrast-Associated Nephropathy.

Authors:  Emilee Wilhelm-Leen; Maria E Montez-Rath; Glenn Chertow
Journal:  J Am Soc Nephrol       Date:  2016-09-29       Impact factor: 10.121

Review 9.  Emergency noninvasive angiography for acute intracerebral hemorrhage.

Authors:  H Khosravani; S A Mayer; A Demchuk; B S Jahromi; D J Gladstone; M Flaherty; J Broderick; R I Aviv
Journal:  AJNR Am J Neuroradiol       Date:  2012-11-01       Impact factor: 3.825

10.  Functional contrast-enhanced CT for evaluation of acute ischemic stroke does not increase the risk of contrast-induced nephropathy.

Authors:  F O Lima; M H Lev; R A Levy; G S Silva; M Ebril; E C de Camargo; S Pomerantz; A B Singhal; D M Greer; H Ay; R Gilberto González; W J Koroshetz; W S Smith; K L Furie
Journal:  AJNR Am J Neuroradiol       Date:  2009-12-31       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.